Genentech Phase/TNF studies

Initial safety studies on tumor necrosis factor began during week of Sept. 23-27 at M.D. Anderson (Houston) and Memorial Sloan Kettering (New York). Genentech said that TNF is its seventh product to enter human clinical trials. The company has previously identified five products in clinical testing.